Champions Oncology(CSBR) - 2025 Q3 - Quarterly Results

Financial Performance - Total revenue for Q3 fiscal 2025 reached $17.0 million, a 42$12.0 million in Q3 fiscal 2024[6] - Gross profit for Q3 fiscal 2025 was $10.4 million, resulting in a gross margin of 61$4.5 million, compared to a loss of $2.6 million in Q3 fiscal 2024[7] - Adjusted EBITDA for Q3 fiscal 2025 was$5.2 million, a significant improvement from an adjusted EBITDA loss of $1.7 million in Q3 fiscal 2024[7] - Adjusted EPS for Q3 fiscal 2025 was$0.38, compared to an adjusted EPS loss of $0.12 in Q3 fiscal 2024[26] - Net income for the nine months ended January 31, 2025, was$6,536 million, compared to a net loss of $7,167 million for the same period in 2024[29] - The company reported a basic net income per share of$0.48 for the nine months ended January 31, 2025, compared to a loss of $0.53 in the same period of 2024[27] Revenue Growth - Total oncology revenue for the nine months ended January 31, 2025, was$44.6 million, a 23.3% increase from $36.2 million in the same period last year[12] - Oncology revenue for the three months ended January 31, 2025, was$17,039 million, a 42% increase from $12,019 million in the same period of 2024[27] - The company signed its first data licensing deal worth up to$8.0 million, marking a key milestone in monetizing its proprietary data platform[4] Expenses and Cost Management - Research and development expenses for Q3 fiscal 2025 decreased by 21.4% to $1.7 million compared to$2.2 million in Q3 fiscal 2024[9] - Total costs and operating expenses for Q3 fiscal 2025 were $12.5 million, a decrease of 14.1$14.6 million in Q3 fiscal 2024[6] - Research and development expenses decreased to $4,862 million for the nine months ended January 31, 2025, from$7,494 million in the same period of 2024[27] Cash and Assets - The company ended the quarter with cash on hand of approximately $3.2 million and has no debt[11] - Cash and cash equivalents rose to$3,202 million as of January 31, 2025, compared to $2,618 million at the end of April 2024[28] - The company reported a net cash provided by operating activities of$946 million for the nine months ended January 31, 2025, compared to a net cash used of $4,321 million in the same period of 2024[29] - Total assets increased to$30,627 million as of January 31, 2025, up from $26,132 million on April 30, 2024[28] Liabilities and Shares - Total current liabilities decreased to$19,870 million as of January 31, 2025, from $21,541 million on April 30, 2024[28] - The weighted average common shares outstanding for basic shares was 13,620,686 for the nine months ended January 31, 2025, compared to 13,538,480 for the same period in 2024[27] - Operating lease right-of-use assets decreased to$5,370 million as of January 31, 2025, from $6,252 million on April 30, 2024[28]